Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Jessica Parezo specializes in strategic patent portfolio counseling, transactional patent diligence, and post-grant proceedings.

Navigating all facets of complex patent transactions, Ms. Parezo’s practice ranges from competitive landscape evaluations to targeted freedom-to-operate analyses, in addition to validity and patentability assessments. She advises on intellectual property and licensing aspects for M&A and other corporate clients, and crafting and negotiating intellectual property provisions of deal agreements.

Ms. Parezo’s practice spans inter partes reviews and advising on district court patent litigations, including early case assessments, and strengthening portfolios poised for litigation.

  • Directed freedom-to-operate, patent validity, and patentability investigations for acquisitions of major pharmaceutical candidates including chimeric antigen receptor, recombinant vaccine, and new chemical entity products.
  • Advised on all intellectual property aspects of a transaction culminating in asset purchase and license purchase agreements for the acquisition of an orphan drug granted fast track FDA designation.
  • Represented Biogen Idec in defeating three IPR challenges by Swiss Pharma against patents covering Tysabri®, Biogen’s biologic drug for multiple sclerosis.
  • Represented Anacor Pharmaceuticals in three IPR proceedings brought by a Coalition for Affordable Drugs entity challenging Orange Book-listed patents for Kerydin®, Anacor’s topical antifungal drug.
  • Directed three successful inter partes reexamination proceedings on behalf of GlaxoSmithKline involving immunization patents owned by Classen Immunotherapies. Advised on co-pending District of Maryland patent litigation.  
  • Represented GlycoVaxyn AG, a start-up biopharmaceutical company, in worldwide prosecution of patents covering an innovative biological conjugation platform for producing vaccines. GlaxoSmithKline subsequently acquired GlycoVaxyn and its early stage vaccines.
  • Represented Merck in procuring patents directed to small molecule pharmaceuticals, including HIV protease inhibitors, angiotensin receptor antagonists, and antifungal compounds.
  • Represented Procter & Gamble in procuring patents directed to antimicrobial quinolones, corticotropin-releasing factor receptor agonists, and various proprietary compounds.
  • Represented Biovail in Hatch-Waxman litigation against Impax in the Eastern District of Pennsylvania involving Biovail’s antidepressant drug Wellbutrin XL®.

Pro Bono

  • Provided employment advice to nonprofit organizations, including local dance company engaged in social justice. 
  • Assisted low-income individuals with navigating Medicare prescription drug coverage.
  • Advised economically disadvantaged DC business entrepreneurs on intellectual property issues.